Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jul 31;15(7):3525-3528.
doi: 10.21037/jtd-23-598. Epub 2023 Jun 20.

Immune checkpoint inhibition in advanced esophageal squamous cell carcinoma: how can we personalise management?

Hannah P Cagney  1 , Russell D Petty  1   2 , Mark A Baxter  1   2
Affiliations
Editorial

Immune checkpoint inhibition in advanced esophageal squamous cell carcinoma: how can we personalise management?

Hannah P Cagney et al. J Thorac Dis. .
No abstract available

Keywords: Immune checkpoint inhibitors; esophageal cancer; precision medicine.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-598/coif). MAB reports consultancy fees from Servier, Honoraria from Ipsen and BMS and support for attending meetings from Servier. RDP reports personal fees from Eli Lilly, Bristol Myers Squib, and Servier, and grants from AstraZeneca, Roche, Sanofi, Merck Sharp & Dohme, Five Prime Therapeutics, and Jansen outside the submitted work. The other author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Emerging approaches to improve immune checkpoint inhibitor responses in ESCC. Figure adapted from Baxter et al. (14) under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0). ICI, immune checkpoint inhibitor; RTK, receptor tyrosine kinase; DDRD, DNA Damage Response Deficient; EGFR, epidermal growth factor receptor; IHC, immunohistochemistry; CNG, copy number gain; CNL, copy number loss; mut, mutation; CTx, chemotherapy.
See this image and copyright information in PMC

Comment on

References

    1. Smyth EC, Lagergren J, Fitzgerald RC, et al. Oesophageal cancer. Nat Rev Dis Primers 2017;3:17048. 10.1038/nrdp.2017.48 - DOI - PMC - PubMed
    1. Kato K, Sun JM, Shah MA, et al. LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study. Ann Oncol 2020;31:abstr S1142-215.
    1. Doki Y, Ajani JA, Kato K, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med 2022;386:449-62. 10.1056/NEJMoa2111380 - DOI - PubMed
    1. Shen L, Kato K, Kim SB, et al. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. J Clin Oncol 2022;40:3065-76. 10.1200/JCO.21.01926 - DOI - PMC - PubMed
    1. Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2020;21:832-42. 10.1016/S1470-2045(20)30110-8 - DOI - PubMed